Enanta files patent infringement suit against Pfizer
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
The ‘265 Patent is based on Enanta’s July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The request stemmed from a 2024 lawsuit by Rampart alleging Egg Medical had infringed its patent
The coating is designed for heat-sealable applications, offering oil and grease resistance on kraft paper and suitable blister coatings for paper and paperboard
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Pregabalin Gel 8% is a novel topical solution for diabetic neuropathic pain
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
Subscribe To Our Newsletter & Stay Updated